Abstract
Polynuclear compounds are a relatively new and successful approach in metal-based cancer chemotherapy as typified by the trinuclear Pt compound BBR3464 which was evaluated in clinical trials. In this review, we discuss newer developments of polynuclear ruthenium, osmium and gold complexes, focusing on their anticancer activity. The compounds presented are often supposed to exert their anticancer activity by different modes of action as compared to established drugs, including newly proposed mechanisms such as enzyme inhibition, crosslinking of biomacromolecules or through photo-activation, though many of the examples are also capable of binding to DNA nucleobases. Important metabolization and chemical characteristics of such compounds are discussed, and if the appropriate data is available, molecular modes of action are highlighted.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / metabolism*
-
Antineoplastic Agents / pharmacology
-
Coordination Complexes / chemistry
-
Coordination Complexes / metabolism*
-
Coordination Complexes / pharmacology
-
Cross-Linking Reagents / chemistry
-
Cross-Linking Reagents / metabolism
-
Cross-Linking Reagents / pharmacology
-
DNA / chemistry
-
DNA / metabolism
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / metabolism
-
Enzyme Inhibitors / pharmacology
-
Gold / chemistry
-
Gold / metabolism*
-
Humans
-
Models, Molecular
-
Neoplasms / drug therapy*
-
Organometallic Compounds / chemistry
-
Organometallic Compounds / metabolism*
-
Organometallic Compounds / pharmacology
-
Osmium / chemistry
-
Osmium / metabolism*
-
Photochemical Processes
-
Ruthenium / chemistry
-
Ruthenium / metabolism*
Substances
-
Antineoplastic Agents
-
Coordination Complexes
-
Cross-Linking Reagents
-
Enzyme Inhibitors
-
Organometallic Compounds
-
Osmium
-
Gold
-
Ruthenium
-
DNA